Navigation Links
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
Date:11/30/2009

AMSTERDAM, November 30 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

The study is currently open for enrollment in centers in Europe and Canada and is designed to serve as a registration trial for European approval.

"We are very pleased to initiate the registration study following excellent clinical results from the phase I/II study with ATIR(TM)." says Dr. Manja Bouman, CEO of Kiadis Pharma. "ATIR(TM) has shown a low TRM at one year post transplantation and a high overall survival in a patient population with no standard treatment options left. As an orphan product addressing a high unmet need, we aim to take advantage of a fast development path for ATIR(TM)."

"As the pioneer of ATIR(TM) I am very excited about this next major development milestone, a multinational registration study" says Dr. Denis Claude Roy of the University of Montreal. "I am a strong believer that ATIR(TM) will open up a whole new treatment field for a very large patient group which currently has no treatment options left."

About ATIR(TM)

ATIR(TM), a donor lymphocyte preparation depleted of alloreactive T-cells, is under development to reduce transplant related mortality (TRM) following an allogeneic hematopoietic stem cell transplantation (HSCT). ATIR(TM) is designed to provide early immune reconstitution to fight infections and remaining tumor cells (by eliminating the use of prophylactic immune suppressants) while preventing acute severe (Grade III
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
6. Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013 Oven Industries, Inc. has ... and temperature sensors since 1964. Expertly designed, ... industrial control system applications. As one of ... a generic, control loop feedback system, which helps minimize ... to adjust a systematic process, using a control element, ...
(Date:5/16/2013)... 2013 Kitware , a ... announces new Phase II SBIR funding from the ... of an open-source, high performance computing (HPC) simulation ... enables researchers to select only the toolkits and ... computation, or analysis tasks. , Manufacturers increasingly ...
(Date:5/16/2013)... As the weather warms, women everywhere are waiting for the ... make a statement with fashion, many change their makeup to ... mixes makeup and sweat to produce, and increase acne breakouts. ... warmer months, Adult Acne treatment , Probiotic Action shares ... to deter breakouts. , Recently, an article from ...
(Date:5/16/2013)... BioInformatics LLC New Market Report – ... Current and Future Opportunities (13-004) , With barriers ... primary cells market continues to increase. In this study, ... often, how satisfied scientists are with commercially available primary ... rate. ,  , Additionally, terminally differentiated cells can ...
Breaking Biology Technology:New PID Temperature Controllers Announced by Oven Industries Inc. 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... , , SOUTH PLAINFIELD, ... the initiation of a Phase 3 trial of ataluren (formerly ... mutation cystic fibrosis (nmCF). Patients with CF lack adequate ... a chloride channel necessary for normal function of the lung, ...
... , , INDIANAPOLIS, Sept. 10 ... Advanced lithium-ion battery maker EnerDel, Inc. today named Richard L. Stanley ... global manufacturing and management experience and a distinguished record of creating ... appointments designed to position EnerDel for continued success in the next ...
... , OXFORD, England, September ... Watkins as Head of the Product & Portfolio,Strategy ... Senior Advisors,and Analysts. , ... "We are,delighted to welcome Nikki to PharmaVentures. Our ...
Cached Biology Technology:PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6Lithium-Ion Battery Maker Names New President 2Lithium-Ion Battery Maker Names New President 3Lithium-Ion Battery Maker Names New President 4Lithium-Ion Battery Maker Names New President 5Lithium-Ion Battery Maker Names New President 6PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy 2
(Date:5/16/2013)... NEW YORK , May 16, 2013 ... market research report is available in its ... Market Forecast & Opportunities, 2018 ... data protection and old security practises such ... driven the growth of biometric technologies in ...
(Date:5/15/2013)... gout risk, new research reveals that vitamin C, also ... levels to a clinically significant degree in patients with ... with allopurinol, appears to have a weak effect on ... the results published in the American College of Rheumatology ... Gout is an inflammatory arthritis that causes excruciating pain ...
(Date:5/15/2013)... to date to examine the efficacy of PARP inhibitor ... breast and ovarian cancer, the oral drug olaparib was ... cancers. Results of the study, led by researchers from ... Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, ... Oncology,s annual meeting in Chicago in early June (Abstract ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... MADISON, WI, September 29, 2008 A plot of ... 110 years of sustainable farming practices can produce similar ... In 1896, Professor J.F. Duggar at the Agricultural ... an experiment to test his theories that sustainable cotton ...
... video clip of Leonard Kleinrock showing his contributions to ... George W. Bush will award the National Medals of ... leading researchers, inventors and innovators, at a ceremony in ... a.m. on Monday, September 29, 2008. Reporters interested in ...
... that inexpensive device boosts fuel economy by up to 20 ... prices, researchers in Pennsylvania are reporting results of laboratory tests ... to a car engine,s fuel injector can boost gas mileage ... precious miles per gallon, they say. Their study is scheduled ...
Cached Biology News:Experiment demonstrates 110 years of sustainable agriculture 28 National Medals of Science awardees to be honored at gala, then the White House 28 National Medals of Science awardees to be honored at gala, then the White House 38 National Medals of Science awardees to be honored at gala, then the White House 48 National Medals of Science awardees to be honored at gala, then the White House 58 National Medals of Science awardees to be honored at gala, then the White House 68 National Medals of Science awardees to be honored at gala, then the White House 78 National Medals of Science awardees to be honored at gala, then the White House 8American Chemical Society's Weekly PressPac -- Sept. 24, 2008 2American Chemical Society's Weekly PressPac -- Sept. 24, 2008 3American Chemical Society's Weekly PressPac -- Sept. 24, 2008 4American Chemical Society's Weekly PressPac -- Sept. 24, 2008 5American Chemical Society's Weekly PressPac -- Sept. 24, 2008 6American Chemical Society's Weekly PressPac -- Sept. 24, 2008 7American Chemical Society's Weekly PressPac -- Sept. 24, 2008 8
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... is a G1 cyclin required for G1-phase ... a proto-oncogene. cyclin D2 can phosphorylate ... Species Reactivity: Human, Mouse, and Rat. ... is particularly well suited for neutralization of ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
Biology Products: